Systematic review and meta-analysis of disitamab vedotin efficacy in urothelial carcinoma
Researchers Find Disitamab Vedotin Shows Activity In Bladder Cancer
This systematic review and meta-analysis evaluates disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metasta…
A new review suggests the drug disitamab vedotin might work for some bladder cancer patients with low or negative HER2 levels.
Disitamab vedotin plus PD-1 inhibitor showed high response rates in urothelial carcinoma patients across six centers
New Drug Combo Shows Strong Results for Advanced Bladder Cancer
This retrospective cohort study evaluated disitamab vedotin combined with a PD-1 inhibitor in 132 patients with locally advanced or metastat…
A new drug pairing shrank tumors in 71% of advanced bladder cancer patients, even those with diabetes or kidney problems.
Neoadjuvant atezolizumab shows spatial biomarker changes in operable urothelial carcinoma patients
How a Bladder Cancer Drug Remodels the Tumor Neighborhood
This single-arm, phase II trial evaluated neoadjuvant atezolizumab in patients with operable urothelial carcinoma.
A bladder cancer drug physically breaks down the walls blocking immune cells in tumors, helping doctors predict which patients will respond …